Table 5.
Data from selected series of lymphoma patients undergoing high-dose therapy and autologous transplant.
| First Author/year | Median Age (range) | n | Design | Conditioning | 100-day TRM | NRM | OS | PFS |
|---|---|---|---|---|---|---|---|---|
| Gopal 2001(2) | 62 (60–68) | 53 | Retrospective | BuMelTT (45%), CY-TBI/CY-VP-16-TBI (45%) | 9.4% | 22% at 4y | 33% at 4y | 24% at 4y |
| Buadi 2006(32) | 66 (60–77) | 93 | Retrospective | BEAM (60%), BEAC (40%) | 5.4% | NA | Median 25m | Median 13m |
| Jantunen 2006(3) | 63 (60–70) | 88 | Retrospective | BEAC (56%), BEAM (39%) | 11% | 19% at 4y | 44% at 5 y | 45% at 5 yrs |
| Gopal 2007(9) | 64 (60–76) | 24 | Prospective | Anti-CD20 RIT (100%) | 0% | 4% at 2y | 59% at 3y | 51% at 3y |
| Jantunen 2008(4) | 63 (60–74) | 463 | Registry | BEAM (73%) | 4.4% | 10.8% at 3y | 60% at 3y | 51% at 3y |
| Wildes 2008(33) | 64 (60–73) | 59 | Retrospective | BEAM (100%) | 8.5% | NA | Median 48m | Median 21m |
| Elstrom 2012(34) | 71 (69–86) | 21 | Retrospective | CBV or BEAM(86%) | 19% | NA | Median 8m | Median 18m |
| Gopal 2014 (this study) | 65 (60–76) | 36 | Prospective | Anti-CD20-RIT+ fludarabine | 0% | 7% at 3y | 54% at 3y | 53% at 3y |
TRM=treatment-related mortality, NRM=non-relapse mortality, OS= overall survivial, PFS=prpgression free survival, Bu=busulfan, Mel=melphalan, TT=thiotepa, CY=cyclophosphamide, TBI=total body irradiation, BEAM=carmustine, etoposide, cytarabine, melphalan, BEAC= carmustine, etoposide, cytarabine, cyclophosphamide, Anti-CD20-RIT= I-131-tositumomab, CBV=cylcophosphamide, carmustine, etoposide